Anacetrapib As a Potential Cardioprotective Strategy

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2017 Dec 22

PMID 29263647

Citations 1

Authors

Belinda A Di Bartolo

Stephen J Nicholls

Affiliations

Soon will be listed here.

Abstract

Cholesteryl ester transfer protein (CETP) facilitates movement of esterified cholesterol between high-density lipoproteins (HDLs) and apolipoprotein B-containing lipoproteins. By virtue of their ability to raise HDL cholesterol and lower low-density lipoprotein cholesterol, pharmacological inhibitors of CETP have received considerable attention as potential new agents in cardiovascular prevention. While early studies of CETP inhibitors have demonstrated a lack of clinical efficacy and potential toxicity, development of the potent CETP inhibitor, anacetrapib, has moved forward, with emerging evidence suggesting a role in reducing cardiovascular events. The experience with anacetrapib and its potential for use in clinical practice are reviewed here.

Citing Articles

High Density Lipoproteins: Metabolism, Function, and Therapeutic Potential.

Jomard A, Osto E Front Cardiovasc Med. 2020; 7:39.

PMID: 32296714 PMC: 7136892. DOI: 10.3389/fcvm.2020.00039.

References

Bots M, Visseren F, Evans G, Riley W, Revkin J, Tegeler C . Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet. 2007; 370(9582):153-160. DOI: 10.1016/S0140-6736(07)61088-5. View

Nicholls S, Brewer H, Kastelein J, Krueger K, Wang M, Shao M . Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA. 2011; 306(19):2099-109. DOI: 10.1001/jama.2011.1649. View

Nissen S, Tardif J, Nicholls S, Revkin J, Shear C, Duggan W . Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007; 356(13):1304-16. DOI: 10.1056/NEJMoa070635. View

Holm Johannsen T, Frikke-Schmidt R, Schou J, Nordestgaard B, Tybjaerg-Hansen A . Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects. J Am Coll Cardiol. 2012; 60(20):2041-8. DOI: 10.1016/j.jacc.2012.07.045. View

Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H . A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 2000; 406(6792):203-7. DOI: 10.1038/35018119. View

Rittershaus C, Miller D, Thomas L, Picard M, Honan C, Emmett C . Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol. 2000; 20(9):2106-12. DOI: 10.1161/01.atv.20.9.2106. View

Thomas T, Zhou H, Karmally W, Ramakrishnan R, Holleran S, Liu Y . CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects. Arterioscler Thromb Vasc Biol. 2017; 37(9):1770-1775. PMC: 5567403. DOI: 10.1161/ATVBAHA.117.309549. View

Wu B, Shrestha S, Ong K, Johns D, Hou L, Barter P . Cholesteryl ester transfer protein inhibition enhances endothelial repair and improves endothelial function in the rabbit. Arterioscler Thromb Vasc Biol. 2015; 35(3):628-36. DOI: 10.1161/ATVBAHA.114.304747. View

Kastelein J, Besseling J, Shah S, Bergeron J, Langslet G, Hovingh G . Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet. 2015; 385(9983):2153-61. DOI: 10.1016/S0140-6736(14)62115-2. View

10.

Barter P . Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Am J Cardiol. 2009; 104(10 Suppl):10E-5E. DOI: 10.1016/j.amjcard.2009.09.014. View

11.

Thompson A, Di Angelantonio E, Sarwar N, Erqou S, Saleheen D, Dullaart R . Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA. 2008; 299(23):2777-88. DOI: 10.1001/jama.299.23.2777. View

12.

Tardif J, Rheaume E, Lemieux Perreault L, Gregoire J, Zada Y, Asselin G . Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. Circ Cardiovasc Genet. 2015; 8(2):372-82. DOI: 10.1161/CIRCGENETICS.114.000663. View

13.

Barter P, Caulfield M, Eriksson M, Grundy S, Kastelein J, Komajda M . Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007; 357(21):2109-22. DOI: 10.1056/NEJMoa0706628. View

14.

Kuhnast S, van der Tuin S, van der Hoorn J, van Klinken J, Simic B, Pieterman E . Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin. Eur Heart J. 2014; 36(1):39-48. PMC: 4286319. DOI: 10.1093/eurheartj/ehu319. View

15.

Nicholls S, Tuzcu E, Brennan D, Tardif J, Nissen S . Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of.... Circulation. 2008; 118(24):2506-14. DOI: 10.1161/CIRCULATIONAHA.108.790733. View

16.

Morehouse L, Sugarman E, Bourassa P, Sand T, Zimetti F, Gao F . Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. J Lipid Res. 2007; 48(6):1263-72. DOI: 10.1194/jlr.M600332-JLR200. View

17.

Simic B, Mocharla P, Crucet M, Osto E, Kratzer A, Stivala S . Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase. Atherosclerosis. 2017; 257:186-194. DOI: 10.1016/j.atherosclerosis.2017.01.011. View

18.

Wu B, Shrestha S, Ong K, Johns D, Dunn L, Hou L . Increasing HDL levels by inhibiting cholesteryl ester transfer protein activity in rabbits with hindlimb ischemia is associated with increased angiogenesis. Int J Cardiol. 2015; 199:204-12. DOI: 10.1016/j.ijcard.2015.07.014. View

19.

Sugano M, Makino N, Sawada S, Otsuka S, Watanabe M, Okamoto H . Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem. 1998; 273(9):5033-6. DOI: 10.1074/jbc.273.9.5033. View

20.

Ference B, Kastelein J, Ginsberg H, Chapman M, Nicholls S, Ray K . Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk. JAMA. 2017; 318(10):947-956. PMC: 5710502. DOI: 10.1001/jama.2017.11467. View